Along these lines, an anti-MUC1-C CAR T cell approach using MAb 3D1 sequences was highly effective against MDA-MB-468 TNBC tumor xenografts and has entered the clinic in a partnership with pharma for the treatment of TNBCs and other MUC1-C-expressing cancers (NCT05239143: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors). Here, MUC1 is linked to cancer.